Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 21:5:107.
doi: 10.12688/wellcomeopenres.15987.2. eCollection 2020.

COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports

Rodrigo M Carrillo-Larco  1   2 , Carlos Altez-Fernandez  3 , Sabrina Ravaglia  4 , Joaquín A Vizcarra  5
Affiliations

COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports

Rodrigo M Carrillo-Larco et al. Wellcome Open Res. .

Abstract

Background: Guillain-Barre Syndrome (GBS) is a neurological autoimmune disease that can lead to respiratory failure and death. Whether COVID-19 patients are at high risk of GBS is unknown. Through a systematic review of case reports, we aimed to summarize the main features of patients with GBS and COVID-19. Methods: Without any restrictions, we searched MEDLINE, Embase, Global Health, Scopus, Web of Science and MedXriv (April 23 rd, 2020). Two reviewers screened and studied titles, abstracts and reports. We extracted information to characterize sociodemographic variables, clinical presentation, laboratory results, treatments and outcomes. Results: Eight reports (n=12 patients) of GBS and COVID-19 were identified; one was a Miller Fisher case. The age ranged between 23 and 77 years, and there were more men (9/102). GBS symptoms started between 5 and 24 days after those of COVID-19. The protein levels in cerebrospinal fluid samples ranged between 40 and 193 mg/dl. None of the cerebrospinal fluid samples tested positive for COVID-19. Six patients debuted with ascendant weakness and three with facial weakness. Five patients had favourable evolution, four remained with relevant symptoms or required critical care and one died; the Miller Fisher case had successful resolution. Conclusions: GBS is emerging as a disease that may appear in COVID-19 patients. Although limited, preliminary evidence appears to suggest that GBS occurs after COVID-19 onset. Practitioners and investigators should have GBS in mind as they look after COVID-19 patients and conduct research on novel aspects of COVID-19. Comparison with GBS patients in the context of another viral outbreak (Zika), revealed similarities and differences that deserves further scrutiny and epidemiological studies.

Keywords: COVID-19; Guillain-Barre Syndrome; neurological complications; pandemic.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. Selection process.
See this image and copyright information in PMC

References

    1. Sedaghat Z, Karimi N: Guillain Barre syndrome associated with COVID-19 infection: A case report. J Clin Neurosci. 2020;76:233–235. 10.1016/j.jocn.2020.04.062 - DOI - PMC - PubMed
    1. Toscano G, Palmerini F, Ravaglia S, et al. : Guillain-Barré Syndrome Associated with SARS-CoV-2. N Engl J Med. 2020;382(26):2574–2576. 10.1056/NEJMc2009191 - DOI - PMC - PubMed
    1. Virani A, Rabold E, Hanson T, et al. : Guillain-Barré Syndrome associated with SARS-CoV-2 infection. IDCases. 2020;e00771. 10.1016/j.idcr.2020.e00771 - DOI - PMC - PubMed
    1. Zhao H, Shen D, Zhou H, et al. : Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020;19(5):383–4. 10.1016/S1474-4422(20)30109-5 - DOI - PMC - PubMed
    1. Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, et al. : Miller Fisher Syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020;95(5):e601–e605. 10.1212/WNL.0000000000009619 - DOI - PubMed

Publication types